Daiichi Sankyo (OTCMKTS:DSNKY – Get Free Report) and Lantheus (NASDAQ:LNTH – Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, dividends, risk, profitability, analyst recommendations and institutional ownership.
Profitability
This table compares Daiichi Sankyo and Lantheus’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Daiichi Sankyo | 12.13% | 16.31% | 6.93% |
| Lantheus | 17.28% | 29.26% | 15.40% |
Institutional & Insider Ownership
99.1% of Lantheus shares are held by institutional investors. 1.7% of Lantheus shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Volatility & Risk
Daiichi Sankyo has a beta of -0.1, indicating that its stock price is 110% less volatile than the S&P 500. Comparatively, Lantheus has a beta of 0.01, indicating that its stock price is 99% less volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of recent recommendations for Daiichi Sankyo and Lantheus, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Daiichi Sankyo | 1 | 1 | 0 | 0 | 1.50 |
| Lantheus | 0 | 11 | 3 | 0 | 2.21 |
Lantheus has a consensus target price of $107.44, indicating a potential upside of 5.54%. Given Lantheus’ stronger consensus rating and higher possible upside, analysts plainly believe Lantheus is more favorable than Daiichi Sankyo.
Earnings and Valuation
This table compares Daiichi Sankyo and Lantheus”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Daiichi Sankyo | $14.10 billion | 2.30 | $1.72 billion | $0.98 | 17.77 |
| Lantheus | $1.54 billion | 4.32 | $233.56 million | $4.06 | 25.07 |
Daiichi Sankyo has higher revenue and earnings than Lantheus. Daiichi Sankyo is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.
Summary
Lantheus beats Daiichi Sankyo on 12 of the 14 factors compared between the two stocks.
About Daiichi Sankyo
Daiichi Sankyo is a Japan-based pharmaceutical company that researches, develops, manufactures and markets medicines. Formed in 2005 through the merger of Sankyo and Daiichi Pharmaceutical, the company has a particular focus on oncology and also develops treatments in areas such as cardiovascular disease and other serious conditions. Its portfolio includes Enhertu (trastuzumab deruxtecan), an antibody-drug conjugate developed in collaboration with AstraZeneca, as well as medicines such as Lixiana (edoxaban) and Vanflyta (quizartinib).
About Lantheus
Lantheus Holdings is a radiopharmaceutical and medical imaging company that develops, manufactures, and commercializes products used to diagnose and manage disease. Its offerings support imaging across several areas of medicine, including oncology and cardiology. The company’s products include Pylarify, a positron emission tomography (PET) imaging agent used to detect prostate cancer; Definity, an ultrasound contrast agent used in cardiac imaging; and TechneLite, a generator that supplies technetium-99m for diagnostic imaging procedures.
Receive News & Ratings for Daiichi Sankyo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Daiichi Sankyo and related companies with MarketBeat.com's FREE daily email newsletter.
